Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trialSara Lonardi, Alberto Sobrero, Gerardo Rosati et al.|Annals of Oncology|2016Cited by 56
Low doses of Bisphenol A have pro-inflammatory and pro-oxidant effects, stimulate lipid peroxidation and increase the cardiotoxicity of Doxorubicin in cardiomyoblastsVincenzo Quagliariello, Nicola Maurea, Carmela Coppola et al.|Environmental Toxicology and Pharmacology|2019Cited by 47
Ozone Exerts Cytoprotective and Anti-Inflammatory Effects in Cardiomyocytes and Skin Fibroblasts after Incubation with DoxorubicinVincenzo Simonetti, Luigi Valdenassi, Vincenzo Quagliariello et al.|Evidence-based Complementary and Alternative Medicine|2019Cited by 27
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents.Claudia De Lorenzo, Giuseppe D’Alessio, Gennaro Riccio et al.|Journal of Clinical Oncology|2010Cited by 4
A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer (mCRC)A. Antonio, Federica Perrone, Maria Carmela Piccirillo et al.|Annals of Oncology|2016Cited by 0